Welcome to our dedicated page for Procaps Group Sa news (Ticker: PROC), a resource for investors and traders seeking the latest updates and insights on Procaps Group Sa stock.
Procaps Group, S.A. (PROC) is frequently in the news as an integrated Latin American healthcare and pharmaceutical services company active in medicinal and botanical manufacturing. Company announcements emphasize its role in developing, manufacturing, and marketing over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, high-potency clinical solutions, and hospital supplies that reach more than 50 countries.
The PROC news feed on Stock Titan aggregates these public communications so readers can follow how Procaps addresses governance, financial reporting, and operational topics. Recent releases have covered the company’s internal investigation into historical accounting matters, delays in filing its Form 20-F, and plans to restate certain historical financial statements. News has also highlighted remediation plans to strengthen internal controls and SOX compliance, along with changes to board composition, committee structures, and executive leadership roles.
Investors and observers can use this page to review Procaps’ updates on financial restructuring efforts, including forbearance agreements with lenders, a secured convertible note subscription agreement, and other steps the company describes as supporting liquidity and long-term sustainability. Regulatory and listing developments are another key theme, with disclosures about Nasdaq notices regarding filing delinquencies, hearing requests, and Nasdaq’s determination to delist the company’s ordinary shares, alongside the company’s statement that trading is expected to transition to the OTC Expert Market.
By consolidating these releases, the PROC news page provides a single place to read about Procaps’ pharmaceutical and nutraceutical activities, governance initiatives, and restructuring plans as described by the company in its own announcements.
Procaps Group (NASDAQ: PROC) has announced a delay in filing its Annual Report on Form 20-F for the fiscal year ending December 31, 2023. The delay is due to the need for additional time to review financial statements, which involves an ongoing internal investigation by the Audit Committee into historical accounting treatments related to a 2012 loan of approximately $2.5 million involving related parties.
The company will not meet the deadline of May 15, 2024, but is working to file the report as soon as possible. A conference call will be held shortly after the filing and earnings release to provide further updates.
Procaps Group (NASDAQ: PROC) has announced a delay in filing its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, due to the need for additional time to review its financial statements related to a 2012 loan. The company expects to file the report before May 15, 2024, and will provide updates accordingly. Despite the delay, Procaps Group anticipates revenue and income growth for the year 2023 compared to 2022.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.